FDA approves Biogen's $56,000 drug for Alzheimer's
The Food and Drug Administration of the US approved on Monday Biogen Inc’s Aducanumab to treat Alzheimer’s disease amidst the controversy of its efficacy. Biogen has pr
Biogen, Denali to partner for development of Parkinson's disease Med
The partnership is bound to attract a lot of attention as Parkinson’s, a debilitating degenerative neuro disease has no known cure. A medicinal program will push both compani
Biogen Pays $124 Million to Develop Gene-Based Therapies
On Thursday, Biogen Inc. will enter into the area of eye-disease treatment by paying Applied Genetic Technologies Corp. (AGTC) about $124 million for licensing its products, and co
